Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan 1;91(1):1-6.
doi: 10.1002/ccd.27196. Epub 2017 Jul 14.

TIcaGrEloR and Absorb bioresorbable vascular scaffold implantation for recovery of vascular function after successful chronic total occlusion recanalization (TIGER-BVS trial): Rationale and study design

Salvatore Brugaletta  1 , Josep Gomez-Lara  2 , Juan Caballero  3 , Luis Ortega-Paz  1 , Luis Teruel  2 , Miriam Jimenez Fernandez  3 , Rafael Romaguera  2 , Vicente Alcalde Martinez  3 , Marcos Ñato  2 , Eduardo Molina Navarro  3 , Joan-Antoni Gomez-Hospital  2 , Concepcion Correa Vilches  3 , Maria Joyera  4 , Angel Cequier  2 , Manel Sabate  1
Affiliations

TIcaGrEloR and Absorb bioresorbable vascular scaffold implantation for recovery of vascular function after successful chronic total occlusion recanalization (TIGER-BVS trial): Rationale and study design

Salvatore Brugaletta et al. Catheter Cardiovasc Interv. .

Abstract

Objectives: To explore the role of ticagrelor versus clopidogrel in coronary blood flow normalization immediately after chronic coronary total occlusion (CTO) recanalization.

Background: Coronary vascular function of a CTO immediately after recanalization is demonstrated to be poor.

Methods: The TIGER BVS is a prospective, double-randomized, open-label, two parallel-group controlled clinical trial to evaluate efficacy of ticagrelor versus clopidogrel in improving vascular function of coronary segment distal to CTO immediately after CTO recanalization. A total of 50 patients who receive CTO PCI will be randomized 1:1 to receive ticagrelor versus clopidogrel at least 3 days before the procedure. Immediately after CTO recanalization with Absorb BVS implantation, a specific study of vascular function under adenosine infusion will be performed. Patients will be therefore randomized 1:1 to receive angiographic follow-up with vascular function and optical coherence tomography analyses at 1- or 3-year follow-up. This study is registered on ClinicalTrials.gov with number NCT02211066.

Conclusions: The TIGER BVS trial will provide the first randomized comparison between ticagrelor versus clopidogrel in recovering vascular function in CTO patients. It will also provide important data on vascular restoration therapy of Absorb BVS in this scenario.

Keywords: antiplatelet therapy; bioabsorbable stent; coronary artery disease.

PubMed Disclaimer

Comment in

Similar articles

See all similar articles

Cited by

Publication types

MeSH terms

Associated data

LinkOut - more resources